知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.066 秒)

    Single variable domain antibodies against OX40L, constructs and therapeutic use
    1.
    发明授权
    Single variable domain antibodies against OX40L, constructs and therapeutic use 有权
    针对OX40L的单可变结构域抗体，构建体和治疗用途

    公开(公告)号：US08962807B2

    公开(公告)日：2015-02-24

    申请号：US13515876

    申请日：2010-12-14

    申请人： Frank Verdonck ,  Sigrid Cornelis ,  Stephanie Staelens

    发明人： Frank Verdonck ,  Sigrid Cornelis ,  Stephanie Staelens

    IPC分类号： C07K16/28 ,  A61K39/00

    CPC分类号： C07K16/2896 ,  A61K2039/505 ,  C07K16/2875 ,  C07K2317/22 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/31 ,  G01N33/6845 ,  G01N33/6854 ,  Y02A50/41 ,  Y02A50/412

    摘要： The present invention relates to immunoglobulin single variable domain sequences that are directed against (as defined herein) OX40L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such immunoglobulin single variable domain sequences. In particular these immunoglobulin single variable domain sequences can block binding of OX40L to OX40. The immunoglobulin single variable domains, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of inflammatory disease and/or disorder such as e.g. asthma, allergic asthma, chronic colitis, Crohn's disease, inflammatory bowel disease, and/or arthrosclerosis.

    摘要翻译： 本发明涉及针对（如本文定义）OX40L的免疫球蛋白单可变结构域序列以及包含或基本上由一个或多个这样的免疫球蛋白单可变结构域组成的化合物或构建体，特别是蛋白质和多肽， 序列。 特别地，这些免疫球蛋白单可变结构域序列可以阻断OX40L与OX40的结合。 免疫球蛋白单可变结构域，化合物和构建体可用于预防，治疗或诊断目的，例如用于治疗炎性疾病和/或病症，例如， 哮喘，过敏性哮喘，慢性结肠炎，克罗恩病，炎性肠病和/或关节动脉硬化。

    Internal ribosome entry site, vector containing same and uses thereof
    7.
    发明授权
    Internal ribosome entry site, vector containing same and uses thereof 失效
    内部核糖体进入位点，含有其的载体及其用途

    公开(公告)号：US06764852B2

    公开(公告)日：2004-07-20

    申请号：US09915060

    申请日：2001-07-25

    申请人： Sigrid Cornelis ,  Rudi Beyaert

    发明人： Sigrid Cornelis ,  Rudi Beyaert

    IPC分类号： C12M1585

    CPC分类号： C12N9/1205 ,  A61K48/00

    摘要： Two isoforms, p110 and p58 of PITSLRE protein kinase, can be translated from the same p110 (a2-2) mRNA by an internal ribosome entry process. Accordingly, p110 and p58, two proteins with punitive functions, are translated from a single mRNA species by using two AUGs within the same reading frame. These two proteins share the 439 C-terminal amino acids that contain the kinase domain. The internal ribosomal entry site (“IRES”) in the polycistronic p110 mRNA is the first IRES completely localized in the coding region of a cellular mRNA. Moreover, it was unexpectedly found that the IRES element is cell cycle regulated. Translation of p58 occurs in the G2/M stage of the cycle.

    摘要翻译： PITSLRE蛋白激酶的两个同种型，p110和p58可以通过内部核糖体进入过程从相同的p110（a2-2）mRNA翻译。 因此，p110和p58具有惩罚性功能的两种蛋白质通过在相同阅读框内使用两个AUG从单个mRNA种类翻译。 这两种蛋白质共享含有激酶结构域的439个C-末端氨基酸。 多分支p110 mRNA中的内部核糖体进入位点（“IRES”）是完全定位于细胞mRNA编码区的第一个IRES。 此外，意外地发现IRES元件是细胞周期调节的。 p58的翻译发生在循环的G2 / M阶段。